Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 2Leukemia 2Esophageal Neoplasms 2Adenocarcinoma Of Esophagus 2Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Prolactinoma 1Pituitary Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Growth Hormone-Secreting Pituitary Adenoma 1Gliosarcoma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Chondrosarcoma 1Central Nervous System Neoplasms 1

Interventions

Dexamethasone 23Melphalan 18Cyclophosphamide 12Filgrastim 10Bortezomib 10Calcium Dobesilate 8Peripheral Blood Stem Cell Transplantation 7daratumumab 6Lenalidomide 6pomalidomide 5dexamethasone acetate 3birtamimab 3Thalidomide 3Radiotherapy 3Interferon-alpha 3Granulocyte Colony-Stimulating Factor 3sargramostim 2isatuximab 2dexamethasone 21-phosphate 2belantamab mafodotin 2Focal Adhesion Protein-Tyrosine Kinases 2Etoposide 2Epoetin Alfa 2Doxycycline 2Busulfan 2siltuximab 1pegfilgrastim 1ixazomib 1fludarabine phosphate 1elotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × Microarray Analysis × Clear all
NCT00520767 2023-12-22

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
35 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡